PRINCETON, N.J., June 1, 2026
Made Scientific has been selected as the manufacturing partner for Columbia University’s NOVAKnee program, a pioneering regenerative medicine initiative developing a first-in-class living biologic total knee replacement designed to transform the treatment of osteoarthritis and severe joint degeneration. The collaboration supports Columbia University’s participation in the Advanced Research Projects Agency for Health (ARPA-H) Novel Innovations for Tissue Regeneration in Osteoarthritis (NITRO) program, an ambitious effort aimed at accelerating next-generation biologic therapies capable of restoring damaged joints through tissue regeneration. Under the agreement, Made Scientific will provide comprehensive technology transfer, process development, analytical development, and GMP manufacturing services for the NOVAKnee platform as it advances toward a planned Phase 1 clinical trial in the United States in 2028. The partnership represents a significant milestone in the evolution of regenerative medicine, bringing together advanced cell therapy manufacturing expertise and cutting-edge biomedical engineering to create a living alternative to conventional knee replacement implants.
NOVAKnee Aims to Redefine Joint Replacement Therapy
Traditional total knee replacement procedures rely on metal and plastic implants designed to mechanically replace damaged joints. While these devices have improved the quality of life for millions of patients, they do not regenerate tissue and can eventually require revision surgeries due to wear, loosening, or mechanical failure. The NOVAKnee platform introduces an entirely different therapeutic concept, replacing artificial materials with a biologic implant engineered to regenerate living tissue. The technology utilizes a biodegradable scaffold seeded with bone and cartilage progenitor cells, creating a living construct capable of integrating with the patient’s body and promoting long-term tissue restoration.
Rather than functioning as a permanent mechanical device, the implant is designed to stimulate biological repair and natural joint regeneration. Researchers believe this approach has the potential to fundamentally change orthopedic treatment by addressing the root causes of tissue degeneration instead of simply replacing damaged structures. If successful, NOVAKnee could establish a new standard for treating osteoarthritis and other debilitating joint disorders affecting millions of patients worldwide.
Advanced Cell Therapy Manufacturing Supports Clinical Development
Advertisement
A critical component of any regenerative medicine program is the ability to manufacture complex cell-based products under strict regulatory and quality standards. As part of the collaboration, Made Scientific will provide Good Manufacturing Practice (GMP) clinical manufacturing services for both NOVAKnee-T and NOVAKnee-L, which include autologous and allogeneic stem cell-based implant configurations. The company’s responsibilities will encompass development of manufacturing processes, analytical testing strategies, technology transfer activities, and production of clinical trial materials suitable for human use.
Manufacturing living biologic products presents unique challenges compared with traditional pharmaceuticals because cellular therapies require precise control of biological characteristics, viability, potency, and consistency throughout production. By leveraging its expertise in autologous and allogeneic cell therapy manufacturing, Made Scientific aims to ensure that the NOVAKnee program meets the rigorous quality standards required for regulatory review and clinical evaluation. The partnership highlights the increasingly important role specialized cell therapy manufacturing organizations play in translating academic research breakthroughs into clinical-stage therapeutic products.
ARPA-H Funding Accelerates Regenerative Medicine Innovation
The NOVAKnee initiative is part of Columbia University’s broader NOVAJoint program, which is supported through ARPA-H’s NITRO initiative focused on advancing tissue regeneration technologies for osteoarthritis treatment. Federal support from ARPA-H reflects growing interest in transformative healthcare innovations capable of addressing major unmet medical needs through biologic engineering and regenerative medicine. Researchers involved in the project believe the convergence of stem cell science, biomaterials engineering, and advanced manufacturing could enable a new generation of therapeutic implants that restore function through biological healing mechanisms.
The planned Phase 1 clinical trial will provide critical safety and feasibility data while establishing a foundation for future development. Beyond knee replacement, the technologies and manufacturing approaches developed through the NOVAKnee program may have broader applications across musculoskeletal medicine and regenerative healthcare. As the field continues to evolve, collaborations between academic institutions, government innovation programs, and specialized biomanufacturing partners are expected to play a central role in bringing advanced regenerative therapies from laboratory research into clinical practice, ultimately creating new treatment options for patients suffering from chronic orthopedic diseases.
Source: Made Scientific press release
